Nuvalent Begins Phase 1 Trial for New HER2-Selective Lung Cancer Treatment

7/22/24 6:31:19 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NUVL alert in real time by email

Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the initiation of HEROEX-1, its Phase 1a/1b clinical trial evaluating its novel HER2-selective inhibitor, NVL-330, for pre-treated patients with HER2-altered non-small cell lung cancer (NSCLC).

Get the next $NUVL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NUVL

Date	Price Target	Rating	Analyst
10/24/2024	$100.00	Neutral	UBS
8/29/2024	$100.00	Overweight	Barclays
4/17/2024	$97.00	Buy	Jefferies
4/1/2024	$69.00 → $110.00	Market Perform → Outperform	Leerink Partners
2/28/2024	$99.00	Buy	Guggenheim
2/23/2024	$105.00	Outperform	Robert W. Baird
9/27/2023	$65.00	Buy	Stifel
8/8/2023	$42.00	Market Perform	SVB Securities

More analyst ratings

$NUVL
Press Releases

Fastest customizable press release news feed in the world

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
Nuvectis Pharma (NASDAQ:NVCT) continues to make strides in precision oncology, gaining momentum following presentations last week at the AACR-NCI-EORTC Symposium where its drug candidate NXP900 demonstrated strong synergy with ALK inhibitors in non-small cell lung cancer (NSCLC) cells that despite being driven by ALK fusions, are resistant to treatment with the market leading ALK Inhibitors, alectinib and lorlatinib, showcasing NXP900's potential to address resistance mechanisms in NSCLC. Also, with the growing anticipation of the data update from NXP800 expected soon from the Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, Nuvectis is positioning itself at the forefron
10/28/24 8:21:00 AM ET
$NUVL
$NVCT
$SMMT
Biotechnology: Pharmaceutical Preparations
Health Care
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
CAMBRIDGE, Mass., Sept. 18, 2024 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its previously announced upsized underwritten public offering of 5,750,000 shares of Class A common stock, which includes 750,000 shares of Class A common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $100.00 per share. The gross proceeds of the offering were approximately $575.0 million, before deducting underwriting discounts and commissions and other o
9/18/24 4:05:00 PM ET
$NUVL
Biotechnology: Pharmaceutical Preparations
Health Care
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
CAMBRIDGE, Mass., Sept. 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of an upsized underwritten public offering of 5,000,000 shares of Class A common stock at a price to the public of $100.00 per share. All shares are being offered by Nuvalent. The gross proceeds to Nuvalent from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $500.0 million. The offering is expected to close on September 18, 2024, subject to the satisfaction of customar
9/16/24 10:23:00 PM ET
$NUVL
Biotechnology: Pharmaceutical Preparations
Health Care

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
Updated Phase 1 dose-escalation data from ARROS-1 and ALKOVE-1 clinical trials continue to support potential best-in-class profiles for zidesamtinib and NVL-655 Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical trials; Pivotal data from both ROS1 and ALK programs now anticipated in 2025 Initiation of ALKAZAR Phase 3 randomized, controlled trial of NVL-655 for treatment-naïve patients with advanced ALK-positive NSCLC anticipated in the first half of 2025 Company to host a conference call today at 8:30 a.m. ET/2:30 p.m. CEST CAMBRIDGE, Mass., Sept. 14, 2024 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating pre
9/14/24 5:00:00 AM ET
$NUVL
Biotechnology: Pharmaceutical Preparations
Health Care
Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles
Updated Phase 1 data from ALKOVE-1 and ARROS-1 clinical trials to be presented at the ESMO Congress 2024 Durable activity of NVL-655 and zidesamtinib in heavily pre-treated patient populations supports ongoing Phase 2 investigation in earlier lines of treatment Company plans to host a conference call on September 14, 2024 at 8:30 a.m. ET/2:30 p.m. CEST following oral presentations at ESMO CAMBRIDGE, Mass., Sept. 9, 2024 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced data from abstracts to be presented at the European Society for Medical O
9/9/24 6:30:00 AM ET
$NUVL
Biotechnology: Pharmaceutical Preparations
Health Care
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results
Company plans to host a conference call in conjunction with oral presentations at ESMO on September 14, 2024, at 8:30 a.m. ET/2:30 p.m. CEST $658.0 million in cash, cash equivalents and marketable securities expected to support operating runway into 2027 CAMBRIDGE, Mass., Aug. 8, 2024 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline progress, reiterated key anticipated milestones, and reported second quarter 2024 financial results.
8/8/24 6:30:00 AM ET
$NUVL
Biotechnology: Pharmaceutical Preparations
Health Care

$NUVL
Leadership Updates

Live Leadership Updates

Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors
CAMBRIDGE, Mass., Oct. 6, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Michael L. Meyers, M.D., Ph.D., to its Board of Directors. An experienced drug developer and medical oncologist who has contributed to the successful development and commercialization of multiple new therapies for patients with cancer, Dr. Meyers has served as a Senior Clinical Advisor to Nuvalent since 2020. "We look forward to
10/6/22 6:30:00 AM ET
$NUVL
Biotechnology: Pharmaceutical Preparations
Health Care
Nuvalent Appoints Anna Protopapas as Chair of Board of Directors
Veteran Biotech Executive with Broad Oncology Perspective to Lead Nuvalent Board as Company Advances its Pipeline of Precisely Targeted Therapies CAMBRIDGE, Mass., March 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical stage biopharmaceutical company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics, as Chair of its Board of Directors. "I am excited to join the Nuvalent Board of Directors and have been impressed
3/31/22 6:30:00 AM ET
$NUVL
Biotechnology: Pharmaceutical Preparations
Health Care
Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
NVL-655 IND cleared by FDA, supporting planned initiation of ALKOVE-1 Phase 1/2 clinical trial in patients with ALK-positive NSCLC and other solid tumors in second quarter of 2022 Enrollment ongoing in ARROS-1 trial of NVL-520 for advanced ROS1-positive NSCLC and other solid tumors Discovery pipeline continues to advance toward two development candidate nominations in 2022 CAMBRIDGE, Mass., March 29, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today reported pipeline and business progress and fourth quarter and full year 2021 financial results.
3/29/22 6:30:00 AM ET
$NUVL
Biotechnology: Pharmaceutical Preparations
Health Care

Nuvalent Begins Phase 1 Trial for New HER2-Selective Lung Cancer Treatment

Chat with this insight

Recent Analyst Ratings for $NUVL

$NUVL Market Insights

Live Market Insights